Drug Trial Radar · NCT06767514
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
780
Planned (sponsor's estimate)
Start
Feb 27, 2025
Primary completion
Apr 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- Summit TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Conditions
- Non-Small Cell Lung Cancer
Interventions
Ivonescimab InjectionBiological
Subject will receive ivonescimab as an IV injection
Pembrolizumab InjectionBiological
Subject will receive Pembrolizumab as an IV injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 36 months
- Progression free survival (PFS)Time frame: Up to approximately 36 months
Locations
292 sites in 17 countries. Site status is shown where the registry gives one.
Clinical Study Site
Chandler, Arizona · Recruiting
Clinical Study Site
Phoenix, Arizona · Recruiting
Clinical Study Site
Hot Springs, Arkansas · Recruiting
Clinical Study Sites
Jonesboro, Arkansas · Recruiting
Clinical Study Site
Alameda, California · Recruiting
Clinical Study Site
Anaheim, California · Recruiting
Clinical Study Site
Beverly Hills, California · Recruiting
Clinical Study Site
Cerritos, California · Recruiting
Clinical Study Site
Los Angeles, California · Recruiting
Clinical Study Site
Los Angeles, California · Recruiting
Clinical Study Site
Orange, California · Recruiting
Clinical Study Site
Oxnard, California · Recruiting
Clinical Study Site
San Diego, California · Recruiting
Clinical Study Site
Sunnyvale, California · Recruiting
Clinical Study Site
Torrance, California · Recruiting
Clinical Study Site
Aurora, Colorado · Recruiting
Clinical Study Site
Denver, Colorado · Recruiting
Clinical Study Site
Grand Junction, Colorado · Recruiting
Clinical Study Site
Lone Tree, Colorado · Recruiting
Clinical Study Site
Loveland, Colorado · Recruiting
Clinical Study Sites
Fort Lauderdale, Florida · Recruiting
Clinical Study Site
Fort Lauderdale, Florida · Recruiting
Clinical Study Site
Jacksonville, Florida · Recruiting
Clinical Study Site
Jacksonville Beach, Florida · Recruiting
Clinical Study Site
North Venice, Florida · Recruiting
Clinical Study Site
Ocala, Florida · Recruiting
Clinical Study Site
Orlando, Florida · Recruiting
Clinical Study Site
Pensacola, Florida · Recruiting
Clinical Study Site
Plantation, Florida · Recruiting
Clinical Study Site
St. Petersburg, Florida · Recruiting
Clinical Study Site
Tallahassee, Florida · Recruiting
Clinical Study Site
Tamarac, Florida · Recruiting
Clinical Study Site
West Palm Beach, Florida · Recruiting
Clinical Study Site
Atlanta, Georgia · Recruiting
Clinical Study Site
Warner Robins, Georgia · Recruiting
Clinical Study Site
Carterville, Illinois · Recruiting
Clinical Study Site
Chicago, Illinois · Recruiting
Clinical Study Site
Chicago, Illinois · Recruiting
Clinical Study Site
Evanston, Illinois · Recruiting
Clinical Study Site
Indianapolis, Indiana · Recruiting
Showing 40 of 292 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.